4D Molecular Therapeutics (FDMT) Competitors $3.53 -0.32 (-8.34%) As of 02:15 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock FDMT vs. ABCL, CDXC, KALV, REPL, BCYC, ANAB, COGT, VECT, SION, and KROSShould you be buying 4D Molecular Therapeutics stock or one of its competitors? The main competitors of 4D Molecular Therapeutics include AbCellera Biologics (ABCL), ChromaDex (CDXC), KalVista Pharmaceuticals (KALV), Replimune Group (REPL), Bicycle Therapeutics (BCYC), AnaptysBio (ANAB), Cogent Biosciences (COGT), VectivBio (VECT), Sionna Therapeutics (SION), and Keros Therapeutics (KROS). These companies are all part of the "pharmaceutical products" industry. 4D Molecular Therapeutics vs. AbCellera Biologics ChromaDex KalVista Pharmaceuticals Replimune Group Bicycle Therapeutics AnaptysBio Cogent Biosciences VectivBio Sionna Therapeutics Keros Therapeutics AbCellera Biologics (NASDAQ:ABCL) and 4D Molecular Therapeutics (NASDAQ:FDMT) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, community ranking, media sentiment, dividends and profitability. Which has more risk & volatility, ABCL or FDMT? AbCellera Biologics has a beta of 0.46, indicating that its stock price is 54% less volatile than the S&P 500. Comparatively, 4D Molecular Therapeutics has a beta of 2.87, indicating that its stock price is 187% more volatile than the S&P 500. Is ABCL or FDMT more profitable? 4D Molecular Therapeutics has a net margin of 0.00% compared to AbCellera Biologics' net margin of -533.32%. AbCellera Biologics' return on equity of -15.73% beat 4D Molecular Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets AbCellera Biologics-533.32% -15.73% -12.22% 4D Molecular Therapeutics N/A -28.00%-26.16% Do institutionals & insiders have more ownership in ABCL or FDMT? 61.4% of AbCellera Biologics shares are owned by institutional investors. Comparatively, 99.3% of 4D Molecular Therapeutics shares are owned by institutional investors. 28.9% of AbCellera Biologics shares are owned by company insiders. Comparatively, 9.6% of 4D Molecular Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Does the media favor ABCL or FDMT? In the previous week, 4D Molecular Therapeutics had 6 more articles in the media than AbCellera Biologics. MarketBeat recorded 15 mentions for 4D Molecular Therapeutics and 9 mentions for AbCellera Biologics. 4D Molecular Therapeutics' average media sentiment score of 0.67 beat AbCellera Biologics' score of 0.42 indicating that 4D Molecular Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AbCellera Biologics 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral 4D Molecular Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger valuation and earnings, ABCL or FDMT? 4D Molecular Therapeutics has lower revenue, but higher earnings than AbCellera Biologics. AbCellera Biologics is trading at a lower price-to-earnings ratio than 4D Molecular Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAbCellera Biologics$23.11M25.89-$146.40M-$0.56-3.584D Molecular Therapeutics$23K7,089.74-$100.84M-$3.18-1.11 Do analysts prefer ABCL or FDMT? AbCellera Biologics presently has a consensus price target of $8.33, indicating a potential upside of 315.63%. 4D Molecular Therapeutics has a consensus price target of $29.56, indicating a potential upside of 739.65%. Given 4D Molecular Therapeutics' higher probable upside, analysts clearly believe 4D Molecular Therapeutics is more favorable than AbCellera Biologics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AbCellera Biologics 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.754D Molecular Therapeutics 1 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.60 Does the MarketBeat Community believe in ABCL or FDMT? 4D Molecular Therapeutics received 2 more outperform votes than AbCellera Biologics when rated by MarketBeat users. However, 76.00% of users gave AbCellera Biologics an outperform vote while only 65.56% of users gave 4D Molecular Therapeutics an outperform vote. CompanyUnderperformOutperformAbCellera BiologicsOutperform Votes5776.00% Underperform Votes1824.00% 4D Molecular TherapeuticsOutperform Votes5965.56% Underperform Votes3134.44% Summary4D Molecular Therapeutics beats AbCellera Biologics on 11 of the 18 factors compared between the two stocks. Get 4D Molecular Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FDMT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FDMT vs. The Competition Export to ExcelMetric4D Molecular TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$163.71M$2.94B$5.40B$8.53BDividend YieldN/A1.72%5.22%4.11%P/E Ratio-1.2431.1826.7419.97Price / Sales7,089.74407.34394.93122.22Price / CashN/A168.6838.2534.62Price / Book0.493.346.874.59Net Income-$100.84M-$72.17M$3.23B$248.18M7 Day Performance12.46%6.07%5.01%2.15%1 Month Performance14.29%9.51%12.82%16.14%1 Year Performance-86.00%-27.14%17.63%8.06% 4D Molecular Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FDMT4D Molecular Therapeutics2.9487 of 5 stars$3.53-8.3%$29.56+737.5%-85.2%$162.55M$23,000.00-1.23120ABCLAbCellera Biologics2.7756 of 5 stars$2.06+1.5%$7.50+264.1%-44.1%$614.75M$28.83M-3.38500Gap UpCDXCChromaDex2.3454 of 5 starsN/A$9.03+∞N/A$611.50M$99.60M787.29120KALVKalVista Pharmaceuticals4.402 of 5 stars$12.18+2.4%$24.83+103.9%+3.0%$605.54MN/A-3.35100News CoveragePositive NewsREPLReplimune Group3.8468 of 5 stars$7.86+1.9%$19.43+147.2%+54.7%$605.34MN/A-2.56210News CoveragePositive NewsUpcoming EarningsBCYCBicycle Therapeutics3.6819 of 5 stars$8.60+3.1%$25.00+190.7%-60.8%$595.14M$25.72M-2.61240Gap UpANABAnaptysBio3.3459 of 5 stars$20.03+2.2%$35.88+79.1%-15.6%$588.48M$111.87M-3.29100Positive NewsGap DownCOGTCogent Biosciences2.3846 of 5 stars$5.13+6.7%$14.29+178.5%-32.3%$584.08MN/A-2.0780News CoveragePositive NewsAnalyst ForecastGap DownVECTVectivBioN/A$16.85flatN/AN/A$573.24M$27.34M0.0030High Trading VolumeSIONSionna TherapeuticsN/A$12.90+4.7%$38.50+198.4%N/A$569.20MN/A0.0035KROSKeros Therapeutics3.2791 of 5 stars$13.74+0.7%$37.00+169.3%-73.0%$558.05M$214.71M-2.64100Positive News Related Companies and Tools Related Companies ABCL Alternatives CDXC Alternatives KALV Alternatives REPL Alternatives BCYC Alternatives ANAB Alternatives COGT Alternatives VECT Alternatives SION Alternatives KROS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FDMT) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 4D Molecular Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share 4D Molecular Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy FDMT Stock Free FDMT Stock Alerts